These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 33139492)

  • 1. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
    Baird L; Yamamoto M
    Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33139492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.
    Baird L; Suzuki T; Takahashi Y; Hishinuma E; Saigusa D; Yamamoto M
    Mol Cell Biol; 2020 Oct; 40(22):. PubMed ID: 32868290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
    Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
    Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
    Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
    Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel NRF2-activated cancer treatments utilizing synthetic lethality.
    Baird L; Kensler TW; Yamamoto M
    IUBMB Life; 2022 Dec; 74(12):1209-1231. PubMed ID: 36200139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
    Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
    PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
    Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
    Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
    Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
    PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose availability is a decisive factor for Nrf2-mediated gene expression.
    Heiss EH; Schachner D; Zimmermann K; Dirsch VM
    Redox Biol; 2013; 1(1):359-65. PubMed ID: 24024172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
    Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
    Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Nrf2/Keap1 system by Wasabi 6-methylthiohexyl isothiocyanate in ARE-mediated NQO1 expression.
    Korenori Y; Tanigawa S; Kumamoto T; Qin S; Daikoku Y; Miyamori K; Nagai M; Hou DX
    Mol Nutr Food Res; 2013 May; 57(5):854-64. PubMed ID: 23390006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells.
    Zhou B; Zhang X; Wang G; Barbour KW; Berger FG; Wang Q
    Bioorg Med Chem; 2019 Jan; 27(1):92-99. PubMed ID: 30473361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
    Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
    Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.